WALTHAM, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that it will present at the following investor conferences:
Morgan Stanley 22nd Annual Global Healthcare Conference
Fireside Chat Date: Friday, September 6, 2024
Fireside Chat Time: 10:00 AM ET
Location: New York, NY
H.C. Wainwright 26th Annual Global Investment Conference
Fireside Chat Date: Monday, September 9, 2024
Fireside Chat Time: 9:30 AM ET
Location: New York, NY
2024 Cantor Global Healthcare Conference
Fireside Chat Date: Wednesday, September 18, 2024
Fireside Chat Time: 10:55 AM ET
Location: New York, NY
Live webcasts of the fireside chats will be available in the investor section of the company’s website at investors.invivyd.com and will be archived for approximately 90 days following the events.
About Invivyd
Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2. The company’s proprietary INVYMAB™ platform approach combines state-of-the-art viral surveillance and predictive modeling with advanced antibody engineering. INVYMAB is designed to facilitate the rapid, serial generation of new monoclonal antibodies (mAbs) to address evolving viral threats. In March 2024, Invivyd received emergency use authorization (EUA) from the U.S. FDA for its first mAb in a planned series of innovative antibody candidates. Visit https://invivyd.com/ to learn more.
Contacts:
Media Relations
(781) 208-0160
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Relations
(781) 208-0160
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$1.94 |
| Daily Change: | 0.08 4.30 |
| Daily Volume: | 4,355,680 |
| Market Cap: | US$415.960M |
October 06, 2025 September 24, 2025 September 04, 2025 August 22, 2025 August 20, 2025 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
